Cenk Sumen - 11 Apr 2022 Form 4 Insider Report for MAXCYTE, INC. (MXCT)

Role
Chief Scientific Officer
Signature
/s/ Brian F. Leaf, Attorney-in-Fact
Issuer symbol
MXCT
Transactions as of
11 Apr 2022
Net transactions value
$0
Form type
4
Filing time
21 Mar 2023, 16:41:26 UTC
Previous filing
17 Mar 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MXCT Employee Stock Option (right to buy) Award $0 +500,000 $0.000000 500,000 11 Apr 2022 Common Stock 500,000 $5.70 Direct F1, F2
transaction MXCT Employee Stock Option (right to buy) Award $0 +120,000 $0.000000 120,000 20 Mar 2023 Common Stock 120,000 $4.19 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 As announced in a press release by the issuer on April 15, 2022, on April 11, 2022 the Issuer awarded a stock option to the Reporting Person as a material inducement to his employment with the Issuer in accordance with Nasdaq Listing Rule 5635(c)(4). The stock option was granted under the Issuer's 2021 Inducement Plan. However, due to an administrative oversight, the stock option grant was not previously reported on a Form 4 as required and is being reported on this report.
F2 25% of the shares underlying this option vest on April 11, 2023 and the remaining 75% vest in 36 equal monthly installments thereafter, subject to the reporting person's continuous service with the Issuer at each vesting date.
F3 25% of the shares underlying this option vest on March 20, 2024 and the remaining 75% vest in 36 equal monthly installments thereafter, subject to the reporting person's continuous service with the Issuer at each vesting date.